This is the second trial conducted by NantCell which will investigate high-affinity natural killer cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.
The QUILT-3.090 trial is a single-center, open-label, Phase 1b/2 clinical trial designed to evaluate the safety and efficacy of several combination therapies, including combinations with aldoxorubicin, in subjects with SCC who have progressed on or after platinum-based chemotherapy and anti-PD1/PD-L1 therapy. This trial is expected to enroll approximately 65 patients.
NantCell is a private subsidiary of NantWorks, LLC. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin, has been out-licensed to NantCell.
CytRx specialises in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.
The company is also expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of a new class of anti-cancer therapies.
Abilita Bio signs multi-target collaboration with Amgen
Innovent treats first cancer patient in Phase I clinical trial of Anti-OX40 Antibody
Parexel Appoints Former FDA Senior Executives to Global Regulatory Consulting Services
Omeros Names Bumol to Board of Directors
Bicycle Therapeutics Awarded GBP 496,000 SBRI Contract to Address Antimicrobial Resistance in Humans
Altasciences Launches New Brand and Website
Synlogic Names Patricia Hurter to Board of Directors
Calliditas Therapeutics announces grant of ODD by US FDA for primary biliary cholangitis